SLGCW
Closed
Somalogic Inc
0.086
-0.034 (-28.33%)
Last Update: 05 Jan 2024 23:52:00
Yesterday: 0.12
Day's Range: 0. - 0.
Send
sign up or login to leave a comment!
When Written:
0.3312
SomaLogic Inc. is a biotechnology company that specializes in the development of protein detection technology. The company was founded in 2000 and is headquartered in Boulder, Colorado. SomaLogic's technology platform is based on the use of modified aptamers, which are short, single-stranded DNA or RNA molecules that can bind to specific target proteins. These modified aptamers are used to detect and quantify proteins in biological samples, such as blood, urine, or saliva.
SomaLogic's technology has a wide range of potential applications, including in the diagnosis and monitoring of diseases, drug development, and personalized medicine. The company has partnerships with several pharmaceutical companies and research institutions to develop and commercialize its technology.
SomaLogic has received funding from several sources, including venture capital firms and government agencies. In 2020, the company raised $121 million in a Series A funding round led by iCarbonX, a Chinese digital health company.
SomaLogic has also been involved in COVID-19 research, developing a blood test that can detect the virus and monitor disease progression. The test has received emergency use authorization from the U.S. Food and Drug Administration.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
SomaLogic's technology has a wide range of potential applications, including in the diagnosis and monitoring of diseases, drug development, and personalized medicine. The company has partnerships with several pharmaceutical companies and research institutions to develop and commercialize its technology.
SomaLogic has received funding from several sources, including venture capital firms and government agencies. In 2020, the company raised $121 million in a Series A funding round led by iCarbonX, a Chinese digital health company.
SomaLogic has also been involved in COVID-19 research, developing a blood test that can detect the virus and monitor disease progression. The test has received emergency use authorization from the U.S. Food and Drug Administration.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!